INFLARX N.V.
INFLARX N.V.
Acción · NL0012661870 · IFRX · A2H7A5 (XNAS)
Resumen Indicadores financieros
0,83 USD
1,17 % 0,010 USD
NASDAQ (XNAS) · Precios actuales y gráficos en MoneyPeak
06.06.2025 23:29

Cotizaciones actuales de INFLARX N.V.

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
IFRX
USD
06.06.2025 23:29
0,83 USD
0,83 USD
-0,12 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % 5,21 % -45,03 % -31,68 % -68,07 % -48,44 % -88,92 %
Asignación de activos
ActivoPorcentaje %
Stock non-US49,50 %
Stock US49,12 %
Cash1,38 %
NotClassified0,00 %
Other0,00 %
Bond0,00 %
Mayores posiciones
SímboloISINNombrePorcentaje %
CRLCharles River Laboratories International Inc 6,62 %
TPLTexas Pacific Land Corporation 5,65 %
FNVFranco-Nevada Corporation 4,85 %
PSKPrairieSky Royalty Ltd 4,63 %
DB1Deutsche Börse AG 4,45 %
ASXASX Limited 4,41 %
ICEIntercontinental Exchange Inc 4,25 %
WPMWheaton Precious Metals Corp 4,08 %
ADMArcher-Daniels-Midland Company 3,93 %
MMCMarsh & McLennan Companies Inc 3,43 %
Distribución por regiones
RegiónPorcentaje %
North America81,33 %
Europe Developed7,36 %
Australasia5,98 %
Asia Developed4,25 %
Japan1,08 %
Africa/Middle East0,00 %
Asia Emerging0,00 %
Europe Emerging0,00 %
Latin America0,00 %
United Kingdom0,00 %
Distribución por sectores
SectorPorcentaje %
Finanzdienstleistungen33,23 %
Grundstoffe22,05 %
Energie18,96 %
Gesundheitswesen8,10 %
Immobilien7,47 %
Basiskonsumgüter5,46 %
Industrieunternehmen2,44 %
Technologie2,30 %
Verbrauchsgüter0,00 %
Telekommunikation0,00 %

Perfil de la empresa para INFLARX N.V. Acción

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Datos maestros del fondo
Emisor Horizon Kinetics
Tipo de valor ETF
Nombre Horizon Kinetics Inflation Beneficiaries ETF
Moneda del fondo USD
Categoría World Large-Stock Growth
fund.
Cifras clave del fondo
Tamaño del fondo 631.168,26 EUR
Estrategia de inversión
The investment seeks long-term growth of capital in real (inflation-adjusted) terms. The fund is an actively-managed ETF that seeks to achieve its investment objective by investing primarily in the equity securities of domestic and foreign companies that are expected to benefit, either directly or indirectly, from rising prices (inflation). The fund's investments in equity securities are generally expected to include common stock, ownership units of publicly traded MLPs, and units of royalty trusts. The fund is non-diversified.

Datos de la empresa

Nombre INFLARX N.V.
Empresa InflaRx N.V.
Símbolo IFRX
Sitio web https://www.inflarx.de
Mercado principal XNAS NASDAQ
WKN A2H7A5
ISIN NL0012661870
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Niels C. Riedemann M.D., Ph.D.
Capitalización de mercado 70 Mio
País Alemania
Moneda USD
Empleados 0,1 T
Dirección Winzerlaer Str. 2, 07745 Jena
Fecha de OPV 2017-11-07

Símbolos de cotización

Nombre Símbolo
Frankfurt IF0.F
NASDAQ IFRX

Otras acciones

Los inversores que tienen INFLARX N.V. también tienen las siguientes acciones en su cartera:
BAIDU INC - ADR
BAIDU INC - ADR Acción
BIONTECH SE ADR
BIONTECH SE ADR Acción
BYD
BYD Acción
DEUTSCHE TELEKOM AG
DEUTSCHE TELEKOM AG Acción
GAZPROM ADR
GAZPROM ADR Certificado de depósito
JD.CO INC - ADR
JD.CO INC - ADR Acción
LYXOR MSCI EUROPE (DR) UCITS ETF - ACC
LYXOR MSCI EUROPE (DR) UCITS ETF - ACC ETF
META PLATFORMS INC
META PLATFORMS INC Acción
MICROSOFT CORP
MICROSOFT CORP Acción
SDCL ENERGY EFFICIENCY INCOME TRUST PLC - ORD GBP0.01
SDCL ENERGY EFFICIENCY INCOME TRUST PLC - ORD GBP0.01 Fondo
SQUARE INC A
SQUARE INC A Acción
VA-Q-TEC AG
VA-Q-TEC AG Acción
Vanguard Energy Fund Admiral Shares
Vanguard Energy Fund Admiral Shares ETF
WEICHAI POWER CO
WEICHAI POWER CO Acción
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025